BL-001-1250 contains a proprietary mixture of proteins and buffer reagents designed to reduce the sIgA cross-reactivity present in certain substrates such as milk. Following ELISA assays in the Biosensis Rapid TM ELISA range have been validated to achieve accurate results using BL-001-1250: BEK-2211, Mature BDNF; Application: human milk One vial of BL-001-1250 contains 1250 ?g of proprietary immunoglobulins, which is sufficient as sample diluent additive for one 96-well plate. Other ELISA assays may also benefit from addition of blocker BL-001-1250, but require optimization of working concentration and assay validation for accurate results.
Product Type:
Immunoassay Blocker
Format:
Lyophilized.
Species Reactivity:
Human
Applications:
ELISA
Application Details:
Immunoassay blocker to reduce or eliminate secretory IgA (sIgA) interference in sandwich ELISA assays for validated sample applications.
Biosensis Brand:
Biosensis®
Shelf Life:
12 months after date of receipt (unopened vial).
Use:
For research use only.
Storage:
Store unopened vial at 2-8°C.
Purification:
Purified
Target:
Secretory IgA immunoassay Blocker for BEK-2211 and similar ELISA assays
The Biosensis Mature BDNF/proBDNF Combo Rapid TM enzyme-linked immunosorbent assay (ELISA) Kit combines individual, but complementary ELISA kits for the two most important BDNF isoforms: Mature BDNF ( BEK-2211 ) and full-length proBDNF ( BEK-2237 ). Both kits are sandwich ELISAs, useful for the quantification of mature BDNF and proBDNF in less than 4 hours in cell culture supernatants, serum, plasma (citrate and EDTA), mouse and rat cell lysates and rat brain extracts only if used as directed, with a simplified protocol and no loss of sensitivity or specificity. Please refer to the most current kit protocols for BEK-2211 (Mature BDNF Rapid TM ELISA) and BEK-2237 (proBDNF Rapid TM ELISA), for specific use instructions for each substrate application, in particular blood samples. BEK-2241 is the preferred Combo kit for human blood samples. The Mature BDNF ELISA kit consists of a pre-coated mouse monoclonal anti-mature BDNF capture antibody, a biotinylated anti-mature BDNF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The proBDNF ELISA kit consists of a pre-coated monoclonal anti-proBDNF capture antibody, a biotinylated anti-mature BDNF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a coloured reaction product which is directly proportional to the concentration of mature BDNF or proBDNF present in samples and protein standards. A BDNF and proBDNF positive control (QC sample) is provided to assure consistent assay performance. Both ELISA kits contain high quality protein calibrators. The Mature BDNF ELISA kit employs a recombinant E.coli-derived human mature BDNF standard approved by the World Health Organization (WHO, www.nibsc.org). The amino acid sequence of mature BDNF is identical for human, mouse, rat and a number of other species. This kit therefore is suitable to measure mature BDNF in all these species and uses the same antibodies and antigen. The proBDNF ELISA kit employs a recombinant mammalian, cleavage-resistant human proBDNF standard produced by Biosensis and validated against externally available proBDNF proteins. Due to a high degree of amino acid sequence homology, mouse and rat proBDNF can be quantified and expressed as human proBDNF equivalents. Internal Biosensis validation suggests that the use of the human standard provided in this kit will provide estimates that are identical, or close, to the actual levels of rat and mouse proBDNF present in rodent samples. Note that accurate proBDNF quantification in human serum and citrate-plasma requires the addition of Heterophilic Antibody Blocker BL-004-500 provided in the kit, and available for purchase separately. This ELISA kit has not been tested for other applications. It has been configured for research use only and is not to be used for diagnostic or clinical procedures.
Background Info:
BDNF belongs to the neurotrophin family and regulates the survival and differentiation of neurons during development. The alterations in BDNF expression induced by various kinds of brain insult including stress, ischemia, seizure activity and hypoglycemia, may contribute to some pathologies such as depression, epilepsy, Alzheimer's, and Parkinson's disease. FUNCTION: Promotes the survival of neuronal populations that are all located either in the central nervous system or directly connected to it. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. SUBUNIT: Monomers and homodimers. Binds to NTRK2/TRKB. SUBCELLULAR LOCATION: Secreted protein. Post Translation Modification (PTM): The propeptide is N-glycosylated and glycosulfated. PTM: Converted into mature BDNF by plasmin (PLG) (By similarity). DISEASE: Defects in BDNF are a cause of congenital central hypoventilation syndrome (CCHS); also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. CCHS is frequently complicated with neurocristopathies such as Hirschsprung disease that occurs in about 16% of CCHS cases. SIMILARITY: Belongs to the NGF-beta family.
Product Type:
ELISA Assay
Species Reactivity:
Human,Mouse,Rat
Immunogen:
See BEK-2211 & BEK-2237 for specific details
Applications:
ELISA
Application Details:
ELISA. For the quantification of Mature BDNF and proBDNF in Culture Supernatant, Serum, Plasma (Citrate), Plasma (EDTA), Cell Lysates, Tissue Homogenates. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
Alternative Names:
Brain-derived neurotrophic factor; Abrineurin
Biosensis Brand:
Rapid
Detection Method:
Colorimetric
Shelf Life:
12 months after date of receipt unopened.
Use:
For research use only.
Kit Components:
The ELISA kit box contains 2 x 96-well pre-coated strip plates per kit (1 x BDNF antibody, 1 x proBDNF antibody coated plate), protein standards, QC sample, detection reagents, heterophilic antibody blocker, wash and sample buffers, substrate buffer and detailed protocols.
Product references:
Please refer to BEK-2211 (Mature BDNF Rapid TM ELISA Kit) and BEK-2237 (proBDNF Rapid TM ELISA Kit) .
Specificity:
Mature BDNF ELISA: Human, mouse, rat BDNF and numerous other species. Although the BDNF assay antibodies are raised against the mature domain, the mature BDNF ELISA preferentially detects mature BDNF over full-length proBDNF.
proBDNF ELISA: Human, mouse and rat proBDNF. The capture antibody used in the proBDNF ELISA kit binds to epitopes within the pro-domain of proBDNF. Thus, this ELISA detects the full length and potentially truncated form of proBDNF, and does not quantify mature BDNF.
Typical limit of detection (LOD) for mature BDNF is less than 2 pg/mL, and 6 pg/mL for proBDNF determined as 150% of the blank value.
Cross Reactivity:
<b>Cross-reactivity of BDNF isoforms:</b><br><br><b>Mature BDNF ELISA:</b><br>No cross-reactivity is observed for nerve growth factor (NGF), neurotrophin-3 (NT-3), NT-4/5, glial cell line-derived neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF165) tested at 25 ng/mL in assay buffer. The reactivity of full-length proBDNF (0.125 ng/mL - 5 ng/mL) was determined in six independent assays using proBDNF proteins from four different sources (mammalian and bacterial, wild-type and mutated). The average cross-reactivity of proBDNF was found to be 5.3% +/- 0.5% in weight (w/v) concentration, or 12.1% +/- 1.2% in molar concentration (mean +/- SEM).<br><br><b>proBDNF ELISA:</b><br>Mature BDNF cross-reactivity was assessed by spiking 28 kDa mature BDNF protein obtained from WHO (www.nibsc.org) into a 1/5 diluted human serum sample at 5 ng/mL, which represents a BDNF concentration level of 25 ng/mL in undiluted, normal human serum. Cross-reactivity of mature BDNF was < 0.3% (w/v), or < 0.1% in molar concentration. The assay antibodies do not cross-react with nerve growth factor (NGF), neurotrophin-3 (NT-3) or NT-4/5.
The Biosensis Mature BDNF/proBDNF Combo Rapid TM enzyme-linked immunosorbent assay (ELISA) Kit combines individual, but complementary ELISA kits for the two most important BDNF isoforms: Mature BDNF ( BEK-2211 ) and full-length proBDNF ( BEK-2217 ). Both kits are sandwich ELISAs, useful for the quantification of mature BDNF and proBDNF in less than 4 hours in cell culture supernatants, serum, plasma (citrate), cell lysates and brain extracts only if used as directed, with a simplified protocol and no loss of sensitivity or specificity. Please refer to the most current kit protocols for BEK-2211 (Mature BDNF Rapid TM ELISA) and BEK-2217 (proBDNF Rapid TM ELISA), for specific use instructions for each substrate application, in particular blood samples. For human blood samples, we suggest the use of BEK-2241 (Mature BDNF/proBDNF Combo kit) . The Mature BDNF ELISA kit consists of a pre-coated mouse monoclonal anti-mature BDNF capture antibody, a biotinylated anti-mature BDNF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The proBDNF ELISA kit consists of a pre-coated polyclonal anti-proBDNF capture antibody, a biotinylated anti-mature BDNF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a coloured reaction product which is directly proportional to the concentration of mature BDNF or proBDNF present in samples and protein standards. A BDNF and proBDNF positive control (QC sample) is provided to assure consistent assay performance. Both ELISA kits contain high quality protein calibrators. The Mature BDNF ELISA kit employs a recombinant E.coli-derived human mature BDNF standard approved by the World Health Organization (WHO, www.nibsc.org). The amino acid sequence of mature BDNF is identical for human, mouse, rat and a number of other species. This kit therefore is suitable to measure mature BDNF in all these species and uses the same antibodies and antigen. The proBDNF ELISA kit employs a recombinant mammalian, cleavage-resistant human proBDNF standard produced by Biosensis and validated against externally available proBDNF proteins. Due to a high degree of amino acid sequence homology, mouse and rat proBDNF can be quantified and expressed as human proBDNF equivalents. Internal Biosensis validation suggests that the use of the human standard provided in this kit will provide estimates that are identical, or close, to the actual levels of rat and mouse proBDNF present in rodent samples. Note that accurate proBDNF quantification in human serum and citrate-plasma requires the addition of Heterophilic Antibody Blocker BL-004-500 provided in the kit, and available for purchase separately. This ELISA kit has not been tested for other applications. It has been configured for research use only and is not to be used for diagnostic or clinical procedures.
Background Info:
BDNF belongs to the neurotrophin family and regulates the survival and differentiation of neurons during development. The alterations in BDNF expression induced by various kinds of brain insult including stress, ischemia, seizure activity and hypoglycemia, may contribute to some pathologies such as depression, epilepsy, Alzheimer's, and Parkinson's disease. FUNCTION: Promotes the survival of neuronal populations that are all located either in the central nervous system or directly connected to it. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. SUBUNIT: Monomers and homodimers. Binds to NTRK2/TRKB. SUBCELLULAR LOCATION: Secreted protein. Post Translation Modification (PTM): The propeptide is N-glycosylated and glycosulfated. PTM: Converted into mature BDNF by plasmin (PLG) (By similarity). DISEASE: Defects in BDNF are a cause of congenital central hypoventilation syndrome (CCHS); also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. CCHS is frequently complicated with neurocristopathies such as Hirschsprung disease that occurs in about 16% of CCHS cases. SIMILARITY: Belongs to the NGF-beta family.
Product Type:
ELISA Assay
Species Reactivity:
Human,Mouse,Rat
Immunogen:
See BEK-2211 & BEK-2217 for specific details
Applications:
ELISA
Application Details:
ELISA. For the quantification of Mature BDNF and proBDNF in Culture Supernatant, Serum, Plasma (Citrate), Cell Lysates, Tissue Homogenates. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
The ELISA kit box contains 2 x 96-well pre-coated strip plates per kit (1 x BDNF antibody, 1 x proBDNF antibody coated plate), protein standards, QC sample, detection reagents, heterophilic antibody blocker, wash and sample buffers, substrate buffer and detailed protocols.
Product references:
Sharma GP et al. (2021) Brain-derived neurotrophic factor promotes immune reconstitution following radiation injury via activation of bone marrow mesenchymal stem cells. PLoS One. 16(10):e0259042 Application: Mouse, culture supernatant. Weaver KR et al. (2021) Neuronal-enriched extracellular vesicles in individuals with IBS: A pilot study of COMT and BDNF. Neurogastroenterol Motil. [Epub ahead of print] Application: Human, plasma, extracellular vesicles.
Specificity:
Mature BDNF ELISA: Human, mouse, rat BDNF and numerous other species. Although the BDNF assay antibodies are raised against the mature domain, the mature BDNF ELISA preferentially detects mature BDNF over full-length proBDNF. proBDNF ELISA: Human, mouse and rat proBDNF. The capture antibody used in the proBDNF ELISA kit binds to epitopes within the pro-domain of proBDNF. Thus, this ELISA detects the full length and potentially truncated form of proBDNF, and does not quantify mature BDNF.
Typical limit of detection (LOD) for mature BDNF is less than 2 pg/mL, and 10 pg/mL for proBDNF determined as 150% of the blank value.
Cross Reactivity:
<b>Cross-reactivity of BDNF isoforms:</b><br><br><b>Mature BDNF ELISA:</b><br>No cross-reactivity is observed for nerve growth factor (NGF), neurotrophin-3 (NT-3), NT-4/5, glial cell line-derived neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF165) tested at 25 ng/mL in assay buffer. The reactivity of full-length proBDNF (0.125 ng/mL - 5 ng/mL) was determined in six independent assays using proBDNF proteins from four different sources (mammalian and bacterial, wild-type and mutated). The average cross-reactivity of proBDNF was found to be 5.3% +/- 0.5% in weight (w/v) concentration, or 12.1% +/- 1.2% in molar concentration (mean +/- SEM).<br><br><b>proBDNF ELISA:</b><br>A cross-reactivity of 2% in weight concentration (0.9% in molar concentration) has been observed for mature BDNF assayed at 25 ng/mL (893 pmol/L) in Assay Diluent A.Due to a high degree of sequence homology, this human proBDNF ELISA kit cross-reacts with the mouse and rat form of proBDNF. Other species have not yet been tested, but cross-reactivity with a wide range of mammalian forms of proBDNF is expected.The antibodies do not cross-react with nerve growth factor (NGF), neurotrophin-3 (NT-3) or NT-4/5.
The Biosensis CE Marked BDNF Rapid enzyme-linked immunosorbent assay (ELISA) Kit is a sandwich ELISA that allows the preferential quantification of mature BDNF in less than 3 hours. This kit consists of a pre-coated mouse monoclonal anti-BDNF capture antibody, a biotinylated anti-BDNF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a colored reaction product which is directly proportional to the concentration of BDNF present in samples and protein standards. This BDNF ELISA kit employs a recombinant human BDNF standard approved by the World Health Organization (WHO, www.nibsc.org ). This kit is suitable to measure mature BDNF in human serum and citrate-treated plasma samples only. The antibodies used in this ELISA kit bind epitopes within the mature domain of the protein and therefore recognize the mature as well as the pro-form of BDNF. However, cross-reactivity to the full-length proBDNF protein is low. This CE Marked BDNF Rapid ELISA [Cat. No. BEK-2211-CE] Kit is approved for in-vitro diagnostic (IVD) applications in the European Economic Area (EEA). It has been developed by Biosensis and is manufactured by Calbiotech Inc. ( www.calbiotech.com ) for Biosensis. BEK-2211-CE is not approved for in-vitro diagnostic (IVD) applications in the United States. For research on human blood, customers MUST order the catalog number BEK-2211 . This research-use-only ELISA kit can be used for human and animal research purposes worldwide, and has been validated for a wider range of sample types and species.
Background Info:
BDNF belongs to the neurotrophin family and regulates the survival and differentiation of neurons during development. The alterations in BDNF expression induced by various kinds of brain insult including stress, ischemia, seizure activity and hypoglycemia, may contribute to some pathologies such as depression, epilepsy, Alzheimer's, and Parkinson's disease. FUNCTION: Promotes the survival of neuronal populations that are all located either in the central nervous system or directly connected to it. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. SUBUNIT: Monomers and homodimers. Binds to NTRK2/TRKB. SUBCELLULAR LOCATION: Secreted protein. Post Translation Modification (PTM): The propeptide is N-glycosylated and glycosulfated. PTM: Converted into mature BDNF by plasmin (PLG) (By similarity). DISEASE: Defects in BDNF are a cause of congenital central hypoventilation syndrome (CCHS); also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. CCHS is frequently complicated with neurocristopathies such as Hirschsprung disease that occurs in about 16% of CCHS cases. SIMILARITY: Belongs to the NGF-beta family.
Product Type:
ELISA Assay
Species Reactivity:
Human
Immunogen:
Recombinant human BDNF with an N-terminal methionine residue, made in E. coli (WHO reference reagent)
Applications:
ELISA
Application Details:
ELISA. For the quantification of Brain-derived neurotrophic factor, mature (BDNF, mature) in Serum, Plasma (Citrate). BEK-2211-CE is expressly designed and tested only for use on human blood and plasma samples. Any other use is deemed "off label use" and thus the performance characteristics of the assay will have to be determined by the end user, and such results are not supported by Biosensis or CalBioTech at this time. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
See BEK-2211-2P-CE protocol insert for specific expiration dating of the kit and its components.
Use:
Approved for in-vitro diagnostic (IVD) applications in the European Economic Area (EEA). It has been developed by Biosensis and is manufactured by Calbiotech Inc. (www.calbiotech.com) for Biosensis.
This kit is not approved for in-vitro diagnostic (IVD) applications in the United States. For research on human blood, customers MUST order the catalog number BEK-2211.
Kit Components:
The ELISA kit box contains 96-well pre-coated strip plate(s), protein standards, detection reagents, wash and sample buffers, substrate buffer and detailed protocols.
Product references:
Reed JL et al. (2021) The effects of high-intensity interval training, Nordic walking and moderate-to-vigorous intensity continuous training on functional capacity, depression and quality of life in patients with coronary artery disease enrolled in cardiac rehabilitation: A randomized controlled trial (CRX study). Prog Cardiovasc Dis. [Epub ahead of print]. Application: Human blood. Valkenborghs SR et al. (2019) Aerobic exercise and consecutive task-specific training (AExaCTT) for upper limb recovery after stroke: A randomized controlled pilot study. Physiother Res Int. [Epub ahead of print]. Application: Human serum.
Specificity:
Human BDNF when used as directed.
Storage:
Store at 2-8°C
Range:
7.8 pg/mL - 500 pg/mL
Sample Type:
Plasma (Citrate),Serum
Sensitivity:
Typical limit of detection (LOD) for BDNF is < 3 pg/mL determined by calculating the mean + 2x standard deviation of mean of blank (n=20).
The Biosensis Mature BDNF Rapid TM enzyme-linked immunosorbent assay (ELISA) Kit is a sandwich ELISA that allows the quantification of mature BDNF in less than 3 hours in cell culture supernatants, serum, plasma (citrate and EDTA), pig serum, cell lysates, brain extracts, human milk and Sheep CSF only if used as directed, with a simplified protocol and no loss of sensitivity or specificity. Please refer to the kit protocol for specific use instructions for each substrate application, in particular blood samples, human milk and CSF. Note that accurate quantification of BDNF in human milk requires a secretory IgA (sIgA) blocker which can be purchased separately ( BL-001-1250 ). For measurement of mature BDNF in CSF samples, please contact us at sales@biosensis.com . This ELISA kit has been tested in independent research laboratories and found to achieve highest reproducibility with intra- and inter-assay CVs as low as 1% and 5%, respectively (Polacchini et al., 2015). This ELISA kit consists of a pre-coated mouse monoclonal anti-mature BDNF capture antibody, a biotinylated anti-mature BDNF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a coloured reaction product which is directly proportional to the concentration of mature BDNF present in samples and protein standards. A BDNF positive control (QC sample) is provided to assure consistent assay performance. This Mature BDNF ELISA kit employs a recombinant human mature BDNF standard approved by the World Health Organization (WHO, www.nibsc.org ). The amino acid sequence of mature BDNF is identical for human, mouse, rat and a number of other species. This kit therefore is suitable to measure mature BDNF in all these species and uses the same antibodies and antigen. Extensive validation has demonstrated that the Mature BDNF Rapid TM ELISA shows only minimal cross-reactivity with proBDNF. Please refer to our Technical Note #5 for further details on ELISA assay validation for BDNF isoform detection and quanification. This ELISA kit has not been tested for other applications. It has been configured for research use only and is not to be used for diagnostic or clinical procedures. For in-vitro diagnostic (IVD) applications in the European Economic Area (EEA), we refer to the CE Marked BDNF ELISA kit (BEK-2211-CE) .
Background Info:
BDNF belongs to the neurotrophin family and regulates the survival and differentiation of neurons during development. The alterations in BDNF expression induced by various kinds of brain insult including stress, ischemia, seizure activity and hypoglycemia, may contribute to some pathologies such as depression, epilepsy, Alzheimer's, and Parkinson's disease. FUNCTION: Promotes the survival of neuronal populations that are all located either in the central nervous system or directly connected to it. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. SUBUNIT: Monomers and homodimers. Binds to NTRK2/TRKB. SUBCELLULAR LOCATION: Secreted protein. Post Translation Modification (PTM): The propeptide is N-glycosylated and glycosulfated. PTM: Converted into mature BDNF by plasmin (PLG) (By similarity). DISEASE: Defects in BDNF are a cause of congenital central hypoventilation syndrome (CCHS); also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. CCHS is frequently complicated with neurocristopathies such as Hirschsprung disease that occurs in about 16% of CCHS cases. SIMILARITY: Belongs to the NGF-beta family.
Product Type:
ELISA Assay
Species Reactivity:
Human,Mouse,Rat
Immunogen:
Recombinant human BDNF with an N-terminal methionine residue, made in E. coli (WHO reference reagent)
Applications:
ELISA
Application Details:
ELISA. For the quantification of Brain-derived neurotrophic factor, mature (BDNF, mature) in Culture Supernatant, Serum, Plasma (Citrate), Plasma (EDTA), Cell Lysates, Tissue Homogenates, Human Milk, CSF. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
The ELISA kit box contains 96-well pre-coated strip plate(s), protein standards, QC sample, detection reagents, wash and sample buffers, substrate buffer and detailed protocols.
Product references:
Total Number of References: 99 Latest Publications (2019-2022):
Meshkat S et al. (2022) Brain-Derived Neurotrophic Factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): A systematic review & meta-analysis Psychiatry Res. 317:114857 Application: Human, serum. Cook A et al. (2022) Activation of TrkB-Akt signaling rescues deficits in a mouse model of SCA6 Sci Adv. [Epub ahead of print] Application: Mouse, brain extracts. Tsotsoros CE et al. (2022) Pilot Associations between Adverse Childhood Experiences, Executive Function, and Brain-Derived Neurotrophic Factor (BDNF) among Adults with Excess Adiposity Obesities. 2, 276-284. Application: Human, serum. Salem HA et al. (2022) Neuroprotective Effect of Morin Hydrate against Attention-Deficit/Hyperactivity Disorder (ADHD) Induced by MSG and/or Protein Malnutrition in Rat Pups: Effect on Oxidative/Monoamines/Inflammatory Balance and Apoptosis Pharmaceuticals. 15, 1012. Application: Rat, brain supernatant. Aldhshan MS & Mizuno TM. (2022) Effect of environmental enrichment on aggression and the expression of brain-derived neurotrophic factor transcript variants in group-housed male mice Behav Brain Res. [Epub ahead of print]. Application: Mouse, brain tissue homogenate. Fujino M et al. (2022) Orally Administered Plasmalogens Alleviate Negative Mood States and Enhance Mental Concentration: A Randomized, Double-Blind, Placebo-Controlled Trial Front Cell Dev Biol. 10:894734 Application: Human, plasma. Abrial E et al. (2022) Investigating Predictive Factors of Suicidal Re-attempts in Adolescents and Young Adults After a First Suicide Attempt, a Prospective Cohort Study. Study Protocol of the SURAYA Project Front. Psychiatry. [Epub ahead of print] Application: Human, plasma. Tanaka-Kanegae R et al. (2022) Sufficiently Elevated Core Body Temperature May Be Necessary to Maintain Cerebral Blood Flow Response throughout the Morning Neurosci Med. 13, 70-90 Application: Human, serum. Merlo S et al. (2022) Microglial polarization differentially affects neuronal vulnerability to the ?-amyloid protein: Modulation by melatonin Biochem Pharmacol. 202:115151 Application: Human, cell culture supernatant. Dalile B et al. (2022) Extruded Wheat Bran Consumption Increases Serum Short-Chain Fatty Acids but Does Not Modulate Psychobiological Functions in Healthy Men: A Randomized, Placebo-Controlled Trial Front Nutr. 9:896154 Application: Human, serum. Agapouda A et al. (2022) Rhodiola Rosea Extract Counteracts Stress in an Adaptogenic Response Curve Manner via Elimination of ROS and Induction of Neurite Outgrowth Oxid. Med. Cell. Longev. [Epub ahead of print] Application: Human, cell lysates. Breazeale S et al. (2022) Symptom cluster profiles following traumatic orthopaedic injuries Injury. [Epub ahead of print] Application: Human, serum. Jaehne EJ et al. (2022) Behavioral phenotyping of a rat model of the BDNF Val66Met polymorphism reveals selective impairment of fear memory Transl Psychiatry. 12(1):93 Application: Rat, acid extracted tissue lysates. Wang RY et al. (2022) The SDF1-CXCR4 Axis Is Involved in the Hyperbaric Oxygen Therapy-Mediated Neuronal Cells Migration in Transient Brain Ischemic Rats. Int J Mol Sci. 23, 1780 Application: Rat, brain tissue homogenate and serum. Hugues N et al. (2022) Time-Dependent Cortical Plasticity during Moderate-Intensity Continuous Training Versus High-Intensity Interval Training in Rats. Cereb Cortex. [Epub ahead of print] Application: Rat, cortical tissue homogenate. Cefis M et al. (2021) Endothelial cells are an important source of BDNF in rat skeletal muscle. Sci Rep. 12(1):311 Application: Rat, skeletal muscle tissue homogenate. Becker AM et al. (2021) Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clin Pharmacol Ther. [Epub ahead of print] Application: Human, plasma. Berbenetz N et al. (2021) The Relationship Between Brain Derived Neurotrophic Factor (BDNF) and Symptoms Following Catheter Ablation for Paroxysmal Atrial Fibrillation (AF)- NEURO-AF Study. Circulation. [Epub ahead of print] Application: Human, serum. Walsh JJ et al. (2021) Short-term ketone monoester supplementation improves cerebral blood flow and cognition in obesity: A randomized cross-over trial. J Physiol. [Epub ahead of print] Application: Human, serum, platelet-poor plasma. Boukhatem I et al. (2021) The brain-derived neurotrophic factor prompts platelet aggregation and secretion. Blood Adv. 5(18):3568-3580 Application: Human, plasma. Yi X et al. (2021) Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease. Front Neurol. 12:680765 Application: Human, serum. Inoue T et al. (2021) Ipsilateral BDNF mRNA expression in the motor cortex positively correlates with motor function of the affected forelimb after intracerebral hemorrhage. Brain Res. [Epub ahead of print] Application: Rat, brain homogenate. Shoshina II et al. (2021) Visual processing and BDNF levels in first-episode schizophrenia. Psychiatry Res. [Epub ahead of print] Application: Human, serum. Cappoli N et al. (2021) Effects of remifentanil on human C20 microglial pro-inflammatory activation. Eur Rev Med Pharmacol Sci. 25(16):5268-5274 Application: Human, cell culture. March B et al. (2021) ELISA-based quantification of neurotrophic growth factors in urine from prostate cancer patients. FASEB Bioadv. [Epub ahead of print] Application: Human, urine. Mori Y et al. (2021) Serum BDNF as a Potential Biomarker of Alzheimer's Disease: Verification Through Assessment of Serum, Cerebrospinal Fluid, and Medial Temporal Lobe Atrophy. Front Neurol. 12:653267 Application: Human, serum. Seno S et al. (2021) Effects of Selective Serotonin Reuptake Inhibitors on Depression-Like Behavior in a Laser-Induced Shock Wave Model. Front Neurol. 12:602038 Application: Mouse, hippocampal homogenates. Medeiros GC et al. (2021) Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. J Affect Disord. 280(Pt A):136-139 Application: Human, plasma. Dorandish S et al. (2021) Differences in the Relative Abundance of ProBDNF and Mature BDNF in A549 and H1299 Human Lung Cancer Cell Media. Int J Mol Sci. 22(13):7059 Application: Human, culture supernatant. Yap NY et al. (2021) Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment. Cytokine. [Epub ahead of print] Application: Human, plasma. Wang L et al. (2021) The mediating effect of brain-derived neurotrophic factor levels on childhood trauma and psychiatric symptoms in patients with first-episode schizophrenia. Aust N Z J Psychiatry. [Epub ahead of print] Application: Human. Mallik SB et al. (2021) Remedial effects of caffeine against depressive-like behaviour in mice by modulation of neuroinflammation and BDNF. Nutr Neurosci. [Epub ahead of print] Application: Mouse. Nomura S et al. (2021) Effects of a Tea Cultivar "MK5601" on Behaviors and Hippocampal Neurotrophin-3 Levels in Middle-Aged Mice. J Nutr Sci Vitaminol (Tokyo). 67(3):170-179 Application: Mouse, hippocampal RIPA homogenates. Caruso GI et al. (2021) SIRT1-Dependent Upregulation of BDNF in Human Microglia Challenged with A?: An Early but Transient Response Rescued by Melatonin. Biomedicines. 9(5):466 Application: Human, cell culture supernatant. Miller KM et al. (2021) Striatal Afferent BDNF Is Disrupted by Synucleinopathy and Partially Restored by STN DBS. J Neurosci. 41(9):2039-52 Application: Rat, tissue homogenates (RIPA). Vickneson K et al. (2021) Cold-induced dishabituation in rodents exposed to recurrent hypoglycaemia. Diabetologia. 64(6):1436-41 Application: Rat, blood. Li P et al. (2021) Intermediation of perceived stress between early trauma and plasma M/P ratio levels in obsessive-compulsive disorder patients. J Affect Disord. 285:105-111 Application: Human, plasma. Lai NS et al. (2021) Increased Serum Levels of Brain-Derived Neurotrophic Factor Contribute to Inflammatory Responses in Patients with Rheumatoid Arthritis. Int. J. Mol. Sci. 22(4):1841 Application: Human, serum and culture supernatants. Pan S et al. (2021) The microRNA-195 - BDNF pathway and cognitive deficits in schizophrenia patients with minimal antipsychotic medication exposure. Transl Psychiatry. 11(1):117 Application: Human, plasma. Miyamoto T et al. (2021) Effect of pedaling cadence on serum levels of brain-derived neurotrophic factor during ergometric exercise in healthy adults. Sport Sci Health. Application: Human, serum. Normann AJ (2020) The Effect of Light Therapy and Acute Aerobic Exercise on Serum Brain Derived Neurotrophic Factor in Older Adults. MSc Thesis. Application: Human, serum. Holze F et al. (2020) Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. [Epub ahead of print]. Application: Human, plasma. Hasler G et al. (2020) The Association Between Adolescent Residential Mobility and Adult Social Anxiety, BDNF and Amygdala-Orbitofrontal Functional Connectivity in Young Adults With Higher Education. Front. Psychiatry. Application: Human, serum. Wallace AW (2020) The Impact of Six Weeks of Intermittent Fasting, With and Without Aerobic Exercise, on Serum BDNF in Young Adult Males. MSc Thesis. Application: Human, serum. Walsh JJ et al. (2020) The Effect of Exogenous Ketone Monoester Ingestion on Plasma BDNF During an Oral Glucose Tolerance Test. Front Physiol. 11:1094. Application: Human, plasma. Meade GM et al. (2020) A Model of Negative Emotional Contagion Between Male-Female Rat Dyads: Effects of Voluntary Exercise on Stress-Induced Behavior and BDNF-TrkB Signaling. Physiol Behav. 113286 Application: Rat, serum. Hutten NRPW et al. (2020) Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. ACS Pharmacol. Transl. Sci. Application: Human, plasma. Barbosa AC et al. (2020) Assessment of BDNF serum levels as a diagnostic marker in children with autism spectrum disorder. Sci Rep. 10(1):17348. Application: Human, serum. Okamura M et al. (2020) Low-Level Inhibition of GABAergic Synapses Enhances Gene Expressions Crucial for Neuronal Plasticity in the Hippocampus After Ischemic Stroke. J Stroke Cerebrovasc Dis. 29(12):105316. Application: Rat, hippocampus homogenate. Payne AJ et al. (2020) The Effects of Alcohol on BDNF and CD5 Dependent Pathways. PhD Thesis. Application: Mouse, RIPA tissue homogenate. Nishiyama M et al. (2020) Homostachydrine is a Xenobiotic Substrate of OCTN1/SLC22A4 and Potentially Sensitizes Pentylenetetrazole-Induced Seizures in Mice. Neurochem Res. [Epub ahead of print]. Application: Mouse, acid-extracted hippocampal homogenate. Lorinczova HT et al. (2020) Co-Administration of Iron and a Bioavailable Curcumin Supplement Increases Serum BDNF Levels in Healthy Adults. Antioxidants (Basel). 9(8):E645. Application: Human serum. Yap NY F et al. (2020) Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer. Breast Cancer Res Treat. [Epub ahead of print]. Application: Human plasma. Vasilopoulou F et al. (2020) Amelioration of BPSD-Like Phenotype and Cognitive Decline in SAMP8 Mice Model Accompanied by Molecular Changes After Treatment With I 2-Imidazoline Receptor Ligand MCR5. Pharmaceutics. 12(5):E475. Application: Mouse hippocampus RIPA-homogenates. Mueller ST et al. (2020) Negative Association Between Left Prefrontal GABA Concentration and BDNF Serum Concentration in Young Adults. Heliyon. 6(5):e04025. Application: Human serum. Chen LF et al. (2020) The NMDA receptor subunit GluN3A regulates synaptic activity-induced and myocyte enhancer factor 2C (MEF2C)-dependent transcription. J Biol Chem. [Epub ahead of print]. Application: Rat neuronal cell lysate, acid-extracted. Companys-Alemany J et al. (2020) A Novel NMDA Receptor Antagonist Protects against Cognitive Decline Presented by Senescent Mice. Pharmaceutics. 12(3), 284. Application: Mouse hippocampal homogenates. Furukawa Y et al. (2020) Citrus Auraptene Induces Expression of Brain-Derived Neurotrophic Factor in Neuro2a Cells. Molecules. 25(5). Application: Mouse Neuro2a culture supernatant. Holze F et al. (2019) Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. [Epub ahead of print]. Application: Human plasma. Sumiyoshi E et al. (2019) Sub-Chronic Consumption of Dark Chocolate Enhances Cognitive Function and Releases Nerve Growth Factors: A Parallel-Group Randomized Trial. Nutrients. 11(11). Application: Human plasma. Sartori A et al. (2019) Interferon-beta, but not Glatiramer Acetate treatment induces gender-specific increase in BDNF serum levels in relapsing-remitting multiple sclerosis female patients. Res J Neuro N Disord. 1:5-18. Application: Human serum. Please refer to our Technical Note #5 for validation experiments disproving the author's claim that the Biosensis Mature BDNF Rapid TM ELISA quantifies total BDNF! Vanicek T et al. (2019) Repetitive Enhancement of Serum BDNF Subsequent to Continuation ECT. Acta Psychiatr Scand. [Epub ahead of print]. Application: Human serum. Gejl AK et al. (2019) Associations between serum and plasma brain-derived neurotrophic factor and influence of storage time and centrifugation strategy. Sci Rep. 9(1):9655. Application: Human serum and EDTA-plasma. Li X et al. (2019) Exercise enhances the expression of brain-derived neurotrophic factor in the hippocampus accompanied by epigenetic alterations in senescence-accelerated mice prone 8. Neurosci Lett. [Epub ahead of print]. Application: Mouse brain homogenates. Yang CY et al. (2019) Panax notoginsenoside Rb1 Restores the Neurotrophic Imbalance Following Photothrombotic Stroke in Rats. Neurotox Res. [Epub ahead of print]. Application: Rat brain homogenates. Du Y et al. (2019) Genome-Wide, Integrative Analysis Implicates Exosome-Derived MicroRNA Dysregulation in Schizophrenia. Schizophr Bull. [Epub ahead of print]. Application: Human serum. Vanicek T et al. (2019) Acute and Subsequent Continuation Electroconvulsive Therapy Elevates Serum BDNF Levels in Patients with Major Depression. Brain Stimul. [In press]. Application: Human serum, plasma. Duart-Castells L et al. (2019) 7,8-dihydroxyflavone blocks the development of behavioral sensitization to MDPV, but not to cocaine: differential role of the BDNF-TrkB pathway. Biochem Pharmacol. [Epub ahead of print]. Application: Mouse RIPA tissue homogenates.
Typical limit of detection (LOD) for BDNF is less than 2 pg/mL, determined as 150% of the blank value.
Cross Reactivity:
No cross-reactivity is observed for nerve growth factor (NGF), neurotrophin-3 (NT-3), NT-4/5, glial cell line-derived neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF165) tested at 25 ng/mL in assay buffer. The reactivity of full-length proBDNF (0.125 ng/mL - 5 ng/mL) was determined in six independent assays using proBDNF proteins from four different sources (mammalian and bacterial, wild-type and mutated). The average cross-reactivity of proBDNF was found to be 5.3% +/- 0.5% in weight (w/v) concentration, or 12.1% +/- 1.2% in molar concentration (mean +/- SEM). Additional proBDNF cross-reactivity experiments were conducted as summarized in our <a class="newA" target="_blank" href="https://www.biosensis.com/documents/enhancedinfo/Technical-Note-5-Mature-BDNF-Isoform-Detection-and-Quantification-by-ELISA.pdf">Technical Note #5</a>.
The Biosensis CE Marked BDNF Rapid enzyme-linked immunosorbent assay (ELISA) Kit is a sandwich ELISA that allows the preferential quantification of mature BDNF in less than 3 hours. This kit consists of a pre-coated mouse monoclonal anti-BDNF capture antibody, a biotinylated anti-BDNF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a colored reaction product which is directly proportional to the concentration of BDNF present in samples and protein standards. This BDNF ELISA kit employs a recombinant human BDNF standard approved by the World Health Organization (WHO, www.nibsc.org ). This kit is suitable to measure mature BDNF in human serum and citrate-treated plasma samples only. The antibodies used in this ELISA kit bind epitopes within the mature domain of the protein and therefore recognize the mature as well as the pro-form of BDNF. However, cross-reactivity to the full-length proBDNF protein is low. This CE Marked BDNF Rapid ELISA [Cat. No. BEK-2211-CE] Kit is approved for in-vitro diagnostic (IVD) applications in the European Economic Area (EEA). It has been developed by Biosensis and is manufactured by Calbiotech Inc. ( www.calbiotech.com ) for Biosensis. BEK-2211-CE is not approved for in-vitro diagnostic (IVD) applications in the United States. For research on human blood, customers MUST order the catalog number BEK-2211 . This research-use-only ELISA kit can be used for human and animal research purposes worldwide, and has been validated for a wider range of sample types and species.
Background Info:
BDNF belongs to the neurotrophin family and regulates the survival and differentiation of neurons during development. The alterations in BDNF expression induced by various kinds of brain insult including stress, ischemia, seizure activity and hypoglycemia, may contribute to some pathologies such as depression, epilepsy, Alzheimer's, and Parkinson's disease. FUNCTION: Promotes the survival of neuronal populations that are all located either in the central nervous system or directly connected to it. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. SUBUNIT: Monomers and homodimers. Binds to NTRK2/TRKB. SUBCELLULAR LOCATION: Secreted protein. Post Translation Modification (PTM): The propeptide is N-glycosylated and glycosulfated. PTM: Converted into mature BDNF by plasmin (PLG) (By similarity). DISEASE: Defects in BDNF are a cause of congenital central hypoventilation syndrome (CCHS); also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. CCHS is frequently complicated with neurocristopathies such as Hirschsprung disease that occurs in about 16% of CCHS cases. SIMILARITY: Belongs to the NGF-beta family.
Product Type:
ELISA Assay
Species Reactivity:
Human
Immunogen:
Recombinant human BDNF with an N-terminal methionine residue, made in E. coli (WHO reference reagent)
Applications:
ELISA
Application Details:
ELISA. For the quantification of Brain-derived neurotrophic factor, mature (BDNF, mature) in Serum, Plasma (Citrate). BEK-2211-CE is expressly designed and tested only for use on human blood and plasma samples. Any other use is deemed "off label use" and thus the performance characteristics of the assay will have to be determined by the end user, and such results are not supported by Biosensis or CalBioTech at this time. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
See BEK-2211-1P-CE protocol insert for specific expiration dating of the kit and its components.
Use:
Approved for in-vitro diagnostic (IVD) applications in the European Economic Area (EEA). It has been developed by Biosensis and is manufactured by Calbiotech Inc. (www.calbiotech.com) for Biosensis.
This kit is not approved for in-vitro diagnostic (IVD) applications in the United States. For research on human blood, customers MUST order the catalog number BEK-2211.
Kit Components:
The ELISA kit box contains 96-well pre-coated strip plate(s), protein standards, detection reagents, wash and sample buffers, substrate buffer and detailed protocols.
Product references:
Reed JL et al. (2021) The effects of high-intensity interval training, Nordic walking and moderate-to-vigorous intensity continuous training on functional capacity, depression and quality of life in patients with coronary artery disease enrolled in cardiac rehabilitation: A randomized controlled trial (CRX study). Prog Cardiovasc Dis. [Epub ahead of print]. Application: Human blood. Valkenborghs SR et al. (2019) Aerobic exercise and consecutive task-specific training (AExaCTT) for upper limb recovery after stroke: A randomized controlled pilot study. Physiother Res Int. [Epub ahead of print]. Application: Human serum.
Specificity:
Human BDNF when used as directed.
Storage:
Store at 2-8°C
Range:
7.8 pg/mL - 500 pg/mL
Sample Type:
Plasma (Citrate),Serum
Sensitivity:
Typical limit of detection (LOD) for BDNF is < 3 pg/mL determined by calculating the mean + 2x standard deviation of mean of blank (n=20).
The Biosensis Mature BDNF Rapid TM enzyme-linked immunosorbent assay (ELISA) Kit is a sandwich ELISA that allows the quantification of mature BDNF in less than 3 hours in cell culture supernatants, serum, plasma (citrate and EDTA), pig serum, cell lysates, brain extracts, human milk and Sheep CSF only if used as directed, with a simplified protocol and no loss of sensitivity or specificity. Please refer to the kit protocol for specific use instructions for each substrate application, in particular blood samples, human milk and CSF. Note that accurate quantification of BDNF in human milk requires a secretory IgA (sIgA) blocker which can be purchased separately ( BL-001-1250 ). For measurement of mature BDNF in CSF samples, please contact us at sales@biosensis.com . This ELISA kit has been tested in independent research laboratories and found to achieve highest reproducibility with intra- and inter-assay CVs as low as 1% and 5%, respectively (Polacchini et al., 2015). This ELISA kit consists of a pre-coated mouse monoclonal anti-mature BDNF capture antibody, a biotinylated anti-mature BDNF detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3',5,5'-tetramethylbenzidine, TMB) yields a coloured reaction product which is directly proportional to the concentration of mature BDNF present in samples and protein standards. A BDNF positive control (QC sample) is provided to assure consistent assay performance. This Mature BDNF ELISA kit employs a recombinant human mature BDNF standard approved by the World Health Organization (WHO, www.nibsc.org ). The amino acid sequence of mature BDNF is identical for human, mouse, rat and a number of other species. This kit therefore is suitable to measure mature BDNF in all these species and uses the same antibodies and antigen. Extensive validation has demonstrated that the Mature BDNF Rapid TM ELISA shows only minimal cross-reactivity with proBDNF. Please refer to our Technical Note #5 for further details on ELISA assay validation for BDNF isoform detection and quanification. This ELISA kit has not been tested for other applications. It has been configured for research use only and is not to be used for diagnostic or clinical procedures. For in-vitro diagnostic (IVD) applications in the European Economic Area (EEA), we refer to the CE Marked BDNF ELISA kit (BEK-2211-CE) .
Background Info:
BDNF belongs to the neurotrophin family and regulates the survival and differentiation of neurons during development. The alterations in BDNF expression induced by various kinds of brain insult including stress, ischemia, seizure activity and hypoglycemia, may contribute to some pathologies such as depression, epilepsy, Alzheimer's, and Parkinson's disease. FUNCTION: Promotes the survival of neuronal populations that are all located either in the central nervous system or directly connected to it. Major regulator of synaptic transmission and plasticity at adult synapses in many regions of the CNS. The versatility of BDNF is emphasized by its contribution to a range of adaptive neuronal responses including long-term potentiation (LTP), long-term depression (LTD), certain forms of short-term synaptic plasticity, as well as homeostatic regulation of intrinsic neuronal excitability. SUBUNIT: Monomers and homodimers. Binds to NTRK2/TRKB. SUBCELLULAR LOCATION: Secreted protein. Post Translation Modification (PTM): The propeptide is N-glycosylated and glycosulfated. PTM: Converted into mature BDNF by plasmin (PLG) (By similarity). DISEASE: Defects in BDNF are a cause of congenital central hypoventilation syndrome (CCHS); also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia. CCHS is frequently complicated with neurocristopathies such as Hirschsprung disease that occurs in about 16% of CCHS cases. SIMILARITY: Belongs to the NGF-beta family.
Product Type:
ELISA Assay
Species Reactivity:
Human,Mouse,Rat
Immunogen:
Recombinant human BDNF with an N-terminal methionine residue, made in E. coli (WHO reference reagent)
Applications:
ELISA
Application Details:
ELISA. For the quantification of Brain-derived neurotrophic factor, mature (BDNF, mature) in Culture Supernatant, Serum, Plasma (Citrate), Plasma (EDTA), Cell Lysates, Tissue Homogenates, Human Milk, CSF. Please download the detailed product insert for complete instructions for the successful use of this ELISA. Use only as directed.
The ELISA kit box contains 96-well pre-coated strip plate(s), protein standards, QC sample, detection reagents, wash and sample buffers, substrate buffer and detailed protocols.
Product references:
Total Number of References: 99 Latest Publications (2019-2022):
Meshkat S et al. (2022) Brain-Derived Neurotrophic Factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): A systematic review & meta-analysis Psychiatry Res. 317:114857 Application: Human, serum. Cook A et al. (2022) Activation of TrkB-Akt signaling rescues deficits in a mouse model of SCA6 Sci Adv. [Epub ahead of print] Application: Mouse, brain extracts. Tsotsoros CE et al. (2022) Pilot Associations between Adverse Childhood Experiences, Executive Function, and Brain-Derived Neurotrophic Factor (BDNF) among Adults with Excess Adiposity Obesities. 2, 276-284. Application: Human, serum. Salem HA et al. (2022) Neuroprotective Effect of Morin Hydrate against Attention-Deficit/Hyperactivity Disorder (ADHD) Induced by MSG and/or Protein Malnutrition in Rat Pups: Effect on Oxidative/Monoamines/Inflammatory Balance and Apoptosis Pharmaceuticals. 15, 1012. Application: Rat, brain supernatant. Aldhshan MS & Mizuno TM. (2022) Effect of environmental enrichment on aggression and the expression of brain-derived neurotrophic factor transcript variants in group-housed male mice Behav Brain Res. [Epub ahead of print]. Application: Mouse, brain tissue homogenate. Fujino M et al. (2022) Orally Administered Plasmalogens Alleviate Negative Mood States and Enhance Mental Concentration: A Randomized, Double-Blind, Placebo-Controlled Trial Front Cell Dev Biol. 10:894734 Application: Human, plasma. Abrial E et al. (2022) Investigating Predictive Factors of Suicidal Re-attempts in Adolescents and Young Adults After a First Suicide Attempt, a Prospective Cohort Study. Study Protocol of the SURAYA Project Front. Psychiatry. [Epub ahead of print] Application: Human, plasma. Tanaka-Kanegae R et al. (2022) Sufficiently Elevated Core Body Temperature May Be Necessary to Maintain Cerebral Blood Flow Response throughout the Morning Neurosci Med. 13, 70-90 Application: Human, serum. Merlo S et al. (2022) Microglial polarization differentially affects neuronal vulnerability to the ?-amyloid protein: Modulation by melatonin Biochem Pharmacol. 202:115151 Application: Human, cell culture supernatant. Dalile B et al. (2022) Extruded Wheat Bran Consumption Increases Serum Short-Chain Fatty Acids but Does Not Modulate Psychobiological Functions in Healthy Men: A Randomized, Placebo-Controlled Trial Front Nutr. 9:896154 Application: Human, serum. Agapouda A et al. (2022) Rhodiola Rosea Extract Counteracts Stress in an Adaptogenic Response Curve Manner via Elimination of ROS and Induction of Neurite Outgrowth Oxid. Med. Cell. Longev. [Epub ahead of print] Application: Human, cell lysates. Breazeale S et al. (2022) Symptom cluster profiles following traumatic orthopaedic injuries Injury. [Epub ahead of print] Application: Human, serum. Jaehne EJ et al. (2022) Behavioral phenotyping of a rat model of the BDNF Val66Met polymorphism reveals selective impairment of fear memory Transl Psychiatry. 12(1):93 Application: Rat, acid extracted tissue lysates. Wang RY et al. (2022) The SDF1-CXCR4 Axis Is Involved in the Hyperbaric Oxygen Therapy-Mediated Neuronal Cells Migration in Transient Brain Ischemic Rats. Int J Mol Sci. 23, 1780 Application: Rat, brain tissue homogenate and serum. Hugues N et al. (2022) Time-Dependent Cortical Plasticity during Moderate-Intensity Continuous Training Versus High-Intensity Interval Training in Rats. Cereb Cortex. [Epub ahead of print] Application: Rat, cortical tissue homogenate. Cefis M et al. (2021) Endothelial cells are an important source of BDNF in rat skeletal muscle. Sci Rep. 12(1):311 Application: Rat, skeletal muscle tissue homogenate. Becker AM et al. (2021) Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clin Pharmacol Ther. [Epub ahead of print] Application: Human, plasma. Berbenetz N et al. (2021) The Relationship Between Brain Derived Neurotrophic Factor (BDNF) and Symptoms Following Catheter Ablation for Paroxysmal Atrial Fibrillation (AF)- NEURO-AF Study. Circulation. [Epub ahead of print] Application: Human, serum. Walsh JJ et al. (2021) Short-term ketone monoester supplementation improves cerebral blood flow and cognition in obesity: A randomized cross-over trial. J Physiol. [Epub ahead of print] Application: Human, serum, platelet-poor plasma. Boukhatem I et al. (2021) The brain-derived neurotrophic factor prompts platelet aggregation and secretion. Blood Adv. 5(18):3568-3580 Application: Human, plasma. Yi X et al. (2021) Serum mBDNF and ProBDNF Expression Levels as Diagnosis Clue for Early Stage Parkinson's Disease. Front Neurol. 12:680765 Application: Human, serum. Inoue T et al. (2021) Ipsilateral BDNF mRNA expression in the motor cortex positively correlates with motor function of the affected forelimb after intracerebral hemorrhage. Brain Res. [Epub ahead of print] Application: Rat, brain homogenate. Shoshina II et al. (2021) Visual processing and BDNF levels in first-episode schizophrenia. Psychiatry Res. [Epub ahead of print] Application: Human, serum. Cappoli N et al. (2021) Effects of remifentanil on human C20 microglial pro-inflammatory activation. Eur Rev Med Pharmacol Sci. 25(16):5268-5274 Application: Human, cell culture. March B et al. (2021) ELISA-based quantification of neurotrophic growth factors in urine from prostate cancer patients. FASEB Bioadv. [Epub ahead of print] Application: Human, urine. Mori Y et al. (2021) Serum BDNF as a Potential Biomarker of Alzheimer's Disease: Verification Through Assessment of Serum, Cerebrospinal Fluid, and Medial Temporal Lobe Atrophy. Front Neurol. 12:653267 Application: Human, serum. Seno S et al. (2021) Effects of Selective Serotonin Reuptake Inhibitors on Depression-Like Behavior in a Laser-Induced Shock Wave Model. Front Neurol. 12:602038 Application: Mouse, hippocampal homogenates. Medeiros GC et al. (2021) Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. J Affect Disord. 280(Pt A):136-139 Application: Human, plasma. Dorandish S et al. (2021) Differences in the Relative Abundance of ProBDNF and Mature BDNF in A549 and H1299 Human Lung Cancer Cell Media. Int J Mol Sci. 22(13):7059 Application: Human, culture supernatant. Yap NY et al. (2021) Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment. Cytokine. [Epub ahead of print] Application: Human, plasma. Wang L et al. (2021) The mediating effect of brain-derived neurotrophic factor levels on childhood trauma and psychiatric symptoms in patients with first-episode schizophrenia. Aust N Z J Psychiatry. [Epub ahead of print] Application: Human. Mallik SB et al. (2021) Remedial effects of caffeine against depressive-like behaviour in mice by modulation of neuroinflammation and BDNF. Nutr Neurosci. [Epub ahead of print] Application: Mouse. Nomura S et al. (2021) Effects of a Tea Cultivar "MK5601" on Behaviors and Hippocampal Neurotrophin-3 Levels in Middle-Aged Mice. J Nutr Sci Vitaminol (Tokyo). 67(3):170-179 Application: Mouse, hippocampal RIPA homogenates. Caruso GI et al. (2021) SIRT1-Dependent Upregulation of BDNF in Human Microglia Challenged with A?: An Early but Transient Response Rescued by Melatonin. Biomedicines. 9(5):466 Application: Human, cell culture supernatant. Miller KM et al. (2021) Striatal Afferent BDNF Is Disrupted by Synucleinopathy and Partially Restored by STN DBS. J Neurosci. 41(9):2039-52 Application: Rat, tissue homogenates (RIPA). Vickneson K et al. (2021) Cold-induced dishabituation in rodents exposed to recurrent hypoglycaemia. Diabetologia. 64(6):1436-41 Application: Rat, blood. Li P et al. (2021) Intermediation of perceived stress between early trauma and plasma M/P ratio levels in obsessive-compulsive disorder patients. J Affect Disord. 285:105-111 Application: Human, plasma. Lai NS et al. (2021) Increased Serum Levels of Brain-Derived Neurotrophic Factor Contribute to Inflammatory Responses in Patients with Rheumatoid Arthritis. Int. J. Mol. Sci. 22(4):1841 Application: Human, serum and culture supernatants. Pan S et al. (2021) The microRNA-195 - BDNF pathway and cognitive deficits in schizophrenia patients with minimal antipsychotic medication exposure. Transl Psychiatry. 11(1):117 Application: Human, plasma. Miyamoto T et al. (2021) Effect of pedaling cadence on serum levels of brain-derived neurotrophic factor during ergometric exercise in healthy adults. Sport Sci Health. Application: Human, serum. Normann AJ (2020) The Effect of Light Therapy and Acute Aerobic Exercise on Serum Brain Derived Neurotrophic Factor in Older Adults. MSc Thesis. Application: Human, serum. Holze F et al. (2020) Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. [Epub ahead of print]. Application: Human, plasma. Hasler G et al. (2020) The Association Between Adolescent Residential Mobility and Adult Social Anxiety, BDNF and Amygdala-Orbitofrontal Functional Connectivity in Young Adults With Higher Education. Front. Psychiatry. Application: Human, serum. Wallace AW (2020) The Impact of Six Weeks of Intermittent Fasting, With and Without Aerobic Exercise, on Serum BDNF in Young Adult Males. MSc Thesis. Application: Human, serum. Walsh JJ et al. (2020) The Effect of Exogenous Ketone Monoester Ingestion on Plasma BDNF During an Oral Glucose Tolerance Test. Front Physiol. 11:1094. Application: Human, plasma. Meade GM et al. (2020) A Model of Negative Emotional Contagion Between Male-Female Rat Dyads: Effects of Voluntary Exercise on Stress-Induced Behavior and BDNF-TrkB Signaling. Physiol Behav. 113286 Application: Rat, serum. Hutten NRPW et al. (2020) Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. ACS Pharmacol. Transl. Sci. Application: Human, plasma. Barbosa AC et al. (2020) Assessment of BDNF serum levels as a diagnostic marker in children with autism spectrum disorder. Sci Rep. 10(1):17348. Application: Human, serum. Okamura M et al. (2020) Low-Level Inhibition of GABAergic Synapses Enhances Gene Expressions Crucial for Neuronal Plasticity in the Hippocampus After Ischemic Stroke. J Stroke Cerebrovasc Dis. 29(12):105316. Application: Rat, hippocampus homogenate. Payne AJ et al. (2020) The Effects of Alcohol on BDNF and CD5 Dependent Pathways. PhD Thesis. Application: Mouse, RIPA tissue homogenate. Nishiyama M et al. (2020) Homostachydrine is a Xenobiotic Substrate of OCTN1/SLC22A4 and Potentially Sensitizes Pentylenetetrazole-Induced Seizures in Mice. Neurochem Res. [Epub ahead of print]. Application: Mouse, acid-extracted hippocampal homogenate. Lorinczova HT et al. (2020) Co-Administration of Iron and a Bioavailable Curcumin Supplement Increases Serum BDNF Levels in Healthy Adults. Antioxidants (Basel). 9(8):E645. Application: Human serum. Yap NY F et al. (2020) Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer. Breast Cancer Res Treat. [Epub ahead of print]. Application: Human plasma. Vasilopoulou F et al. (2020) Amelioration of BPSD-Like Phenotype and Cognitive Decline in SAMP8 Mice Model Accompanied by Molecular Changes After Treatment With I 2-Imidazoline Receptor Ligand MCR5. Pharmaceutics. 12(5):E475. Application: Mouse hippocampus RIPA-homogenates. Mueller ST et al. (2020) Negative Association Between Left Prefrontal GABA Concentration and BDNF Serum Concentration in Young Adults. Heliyon. 6(5):e04025. Application: Human serum. Chen LF et al. (2020) The NMDA receptor subunit GluN3A regulates synaptic activity-induced and myocyte enhancer factor 2C (MEF2C)-dependent transcription. J Biol Chem. [Epub ahead of print]. Application: Rat neuronal cell lysate, acid-extracted. Companys-Alemany J et al. (2020) A Novel NMDA Receptor Antagonist Protects against Cognitive Decline Presented by Senescent Mice. Pharmaceutics. 12(3), 284. Application: Mouse hippocampal homogenates. Furukawa Y et al. (2020) Citrus Auraptene Induces Expression of Brain-Derived Neurotrophic Factor in Neuro2a Cells. Molecules. 25(5). Application: Mouse Neuro2a culture supernatant. Holze F et al. (2019) Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. Neuropsychopharmacology. [Epub ahead of print]. Application: Human plasma. Sumiyoshi E et al. (2019) Sub-Chronic Consumption of Dark Chocolate Enhances Cognitive Function and Releases Nerve Growth Factors: A Parallel-Group Randomized Trial. Nutrients. 11(11). Application: Human plasma. Sartori A et al. (2019) Interferon-beta, but not Glatiramer Acetate treatment induces gender-specific increase in BDNF serum levels in relapsing-remitting multiple sclerosis female patients. Res J Neuro N Disord. 1:5-18. Application: Human serum. Please refer to our Technical Note #5 for validation experiments disproving the author's claim that the Biosensis Mature BDNF Rapid TM ELISA quantifies total BDNF! Vanicek T et al. (2019) Repetitive Enhancement of Serum BDNF Subsequent to Continuation ECT. Acta Psychiatr Scand. [Epub ahead of print]. Application: Human serum. Gejl AK et al. (2019) Associations between serum and plasma brain-derived neurotrophic factor and influence of storage time and centrifugation strategy. Sci Rep. 9(1):9655. Application: Human serum and EDTA-plasma. Li X et al. (2019) Exercise enhances the expression of brain-derived neurotrophic factor in the hippocampus accompanied by epigenetic alterations in senescence-accelerated mice prone 8. Neurosci Lett. [Epub ahead of print]. Application: Mouse brain homogenates. Yang CY et al. (2019) Panax notoginsenoside Rb1 Restores the Neurotrophic Imbalance Following Photothrombotic Stroke in Rats. Neurotox Res. [Epub ahead of print]. Application: Rat brain homogenates. Du Y et al. (2019) Genome-Wide, Integrative Analysis Implicates Exosome-Derived MicroRNA Dysregulation in Schizophrenia. Schizophr Bull. [Epub ahead of print]. Application: Human serum. Vanicek T et al. (2019) Acute and Subsequent Continuation Electroconvulsive Therapy Elevates Serum BDNF Levels in Patients with Major Depression. Brain Stimul. [In press]. Application: Human serum, plasma. Duart-Castells L et al. (2019) 7,8-dihydroxyflavone blocks the development of behavioral sensitization to MDPV, but not to cocaine: differential role of the BDNF-TrkB pathway. Biochem Pharmacol. [Epub ahead of print]. Application: Mouse RIPA tissue homogenates.
Typical limit of detection (LOD) for BDNF is less than 2 pg/mL, determined as 150% of the blank value.
Cross Reactivity:
No cross-reactivity is observed for nerve growth factor (NGF), neurotrophin-3 (NT-3), NT-4/5, glial cell line-derived neurotrophic factor (GDNF) and vascular endothelial growth factor (VEGF165) tested at 25 ng/mL in assay buffer. The reactivity of full-length proBDNF (0.125 ng/mL - 5 ng/mL) was determined in six independent assays using proBDNF proteins from four different sources (mammalian and bacterial, wild-type and mutated). The average cross-reactivity of proBDNF was found to be 5.3% +/- 0.5% in weight (w/v) concentration, or 12.1% +/- 1.2% in molar concentration (mean +/- SEM). Additional proBDNF cross-reactivity experiments were conducted as summarized in our <a class="newA" target="_blank" href="https://www.biosensis.com/documents/enhancedinfo/Technical-Note-5-Mature-BDNF-Isoform-Detection-and-Quantification-by-ELISA.pdf">Technical Note #5</a>.
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.